Methods for Treating Migraine Through CAMK2A Inhibition in Trigeminal Ganglion Nociceptors Identified by Single-Cell Transcriptomic Analysis — USPTO Provisional Patent Specification

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Provisional patent specification (Ritschel Research, filed 2026) disclosing methods and compositions for treating migraine through inhibition of calcium/calmodulin-dependent protein kinase II alpha (CAMK2A) in trigeminal ganglion nociceptors. Lead compounds were identified by a computational pipeline applied to the human TG snRNA-seq atlas GSE197289 (38,028 nuclei from 3 donors; Yang et al., Neuron 2022). ScVI dimensionality reduction and Leiden clustering identified 16 cell populations; a migraine nociceptor gene signature (CGRP pathway, TRP channels, Nav channels, GWAS-implicated genes) identified clusters 14, 8, and 12 as high-priority nociceptor populations. Wilcoxon differential expression yielded 5,530 upregulated genes. ChEMBL drug screening against neurologically-filtered targets identified 62 NOVEL_ALL CAMK2A inhibitor candidates. Lead compounds include midostaurin (FDA-approved, pChEMBL 7.70), lestaurtinib (CAMK2A+TrkA/TrkB, pChEMBL 8.00), and CHEMBL573578 (pChEMBL 8.10), all patent-clear for the disclosed migraine/trigeminal CAMK2A indication. Companion preprint: github.com/glenritschel/migraine-tg-scrna.

Fields of Study & Subjects

Migraine and Headache Studies Pain Mechanisms and Treatments Ion Channels and Receptors

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
22 March 2026
Language
EN